Absolute Eosinophil Count Predicts Intensive Care Unit Transfer Among Elderly COVID-19 Patients From General Isolation Wards

Jinjin Huang 1†, Zhicheng Zhang2,3†, Shunfang Liu4, Chen Gong4, Liping Chen2, Guo Ai5, Xiaodong Zhu6, Chunli Zhang7 and Dengju Li1*

1 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2 Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 3 Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, United States, 4 Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 5 Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 6 Department of Oncology, Huang Gang Central Hospital, Huanggang, China, 7 Department of Endocrinology, Huang Gang Central Hospital, Huanggang, China

Objectives: As of June 1, 2020, coronavirus disease 2019 (COVID-19) has caused a global pandemic and resulted in over 370,000 deaths worldwide. Early identification of COVID-19 patients who need to be admitted to the intensive care unit (ICU) helps to improve the outcomes. We aim to investigate whether absolute eosinophil count (AEC) can predict ICU transfer among elderly COVID-19 patients from general isolation wards.

Methods: A retrospective study of 94 elderly patients older than 60 years old with COVID-19 was conducted. We compared the basic clinical characteristics and levels of inflammation markers on admission to general isolation wards and the needs for ICU transfer between the eosinopenia (AEC on admission < 20 cells/µl) and non-eosinopenia (AEC ≥20 cells/µl) groups.

Results: There was a significantly higher ICU transfer rate in the eosinopenia group than in the non-eosinopenia group (51 vs. 9%, P < 0.001). Multivariate analysis revealed that eosinopenia was associated with an increased risk of ICU transfer in elderly COVID-19 patients [adjusted odds ratio (OR) 6.12 (95% CI, 1.23–30.33), P = 0.027] after adjustment of age, lymphocyte count, neutrophil count, C-reactive protein (CRP), and ferritin levels. The eosinopenia group had higher levels of CRP, ferritin, and cytokines [interleukin-2 receptor (IL-2R), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), and tumor necrosis factor-α (TNF-α)] than the non-eosinophil group (P < 0.001). The area under the curve of AEC on admission for predicting ICU transfer among elderly COVID-19 patients was 0.828 (95% CI, 0.732–0.923). The best cut-off value of AEC was 25 cells/µl with a sensitivity of 91% and a specificity of 71%, respectively.

Conclusion: Absolute eosinophil count on admission is a valid predictive marker for ICU transfer among elderly COVID-19 patients from general isolation wards and, therefore, can help case triage and optimize ICU utilization, especially for health care facilities with limited ICU capacity.

Keywords: COVID-19, eosinophils, prediction, severity, intensive care unit
INTRODUCTION

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been spreading worldwide with over 6 million cases and more than 370,000 deaths by June 1, 2020 (1, 2). A study of 34,249 COVID-19 patients in Spain found that patients aged ≥60 years accounted for 68% of hospitalizations, 70% of intensive care unit (ICU) admissions, and 94% of mortalities (3). It is implied that elderly COVID-19 patients are more likely to have critical progression, which poses a major challenge in healthcare facilities with limited ICU capacity (4, 5).

Currently, early discrimination of elderly COVID-19 patients with ICU requirement remains challenging in clinics. Recently, the traditional inflammation markers, such as C-reactive protein (CRP) (6), ferritin (7), and cytokines (8), are considered as predictive markers for COVID-19 severity. However, these inflammation indicators are usually expensive and time-consuming (9). Thus, a cost-effective, convenient, and fast predictive marker for severe elderly patients with COVID-19 is highly demanded during this pandemic.

Eosinophils are multifunctional cells involved in inflammatory response triggered by diverse stimuli (10). It is already known that acute bacterial infection would result in eosinopenia (11). Some studies have found that eosinopenia on ICU admission could be a useful biomarker for children mortality (12), 28-day mortality (13), unexpected ICU readmission, and post-ICU mortality (14). However, there is no evidence showing that eosinopenia and ICU admission of COVID-19 are closely relevant. Therefore, our study aims to evaluate the value of absolute eosinophil count (AEC) on admission as a predictive marker for ICU transfer among elderly COVID-19 patients from general isolation wards.

METHODS

Study Design

This retrospective study included COVID-19 elderly patients aged ≥60 years from four general wards at the Sino-French New City Branch of Tongji Hospital in Wuhan between February 10, 2020 and February 20, 2020. Exclusion criteria included: (1) patients who had taken corticosteroids before admission, (2) patients who died within 24 h after admission, and (3) patients with a history of allergies and parasitic infections. The protocol of our study was approved by the Tongji Hospital Ethics Committee.

Criteria of ICU Transfer for COVID-19

The criteria of ICU transfer for elderly COVID-19 patients included: (1) severe dyspnea that responds inadequately to initial emergency therapy, (2) changes in mental status (confusion, lethargy, coma, etc.), (3) persistent or worsening hypoxemia and/or severely worsening respiratory acidosis despite supplemental oxygen and non-invasive ventilation, and (4) the need for invasive mechanical ventilation and/or hemodynamic instability.

Data Collection

Clinical data were extracted from electronic medical records, including age, sex, comorbidities, and blood routine and blood biochemistry values on admission. Records of inflammation indicators, such as CRP, ferritin, and cytokines [interleukin-2 receptor (IL-2R), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), and tumor necrosis factor-α (TNF-α)], were also collected on admission.

Laboratory Procedures

The levels of IL-2R, IL-8, IL-10, and TNF-α in serum were measured according to an automatic procedure of a solid-phase two-site chemiluminescent immunoassay via the IMMULITE 1000 Analyzer (Siemens, Munich, Germany). The level of IL-6 was measured using the electrochemiluminescence method (Roche Diagnostics, Basel, Switzerland).

AEC Profiling

Peripheral blood samples of our enrolled patients were assayed for full blood panel counting including AEC on the Sysmex XS-800i (Sysmex Shanghai Ltd., Shanghai, China) as per the manufacturer’s protocol. In accordance with the normal range of AEC in the Chinese population (15), we defined eosinopenia as AEC <20 cells/μl and non-eosinopenia as AEC ≥20 cells/μl. According to AEC on admission, the patients were divided into the eosinopenia group and the non-eosinopenia group.

Statistical Analysis

Continuous variables were described as means (±standard deviation, SD) or medians (interquartile ranges, IQRs) according to their distributions checked by Kolmogorov–Smirnov-test. Student’s t-test or Mann–Whitney U-test was used to compare continuous variables. Categorical variables were compared by chi-square or Fisher’s exact-tests. Variables with P-value < 0.10 on univariate analysis were tested in multivariate analysis. The odds ratio (OR) along with the 95% confidence interval (CI) was reported. The receiver operating characteristics (ROC) curve and the area under the curve (AUC) were calculated for AEC in predicting ICU transfer of patients on admission. The best eosinophil cut-off value was decided depending on the Youden index. All statistical analyses were conducted using GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA) 16.0 and STATA 15 (StataCorp, College Station, TX, USA). A two-tailed P-value < 0.05 was considered to be statistically significant.

Abbreviations: AEC, absolute eosinophil count; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ICU, intensive care unit; CRP, C-reactive protein; HS-CtNL, hypersensitive cardiac troponin I; NT-ProBNP, NT-ProB-type natriuretic peptide; IL-2R, interleukin-2 receptor; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; IQR, interquartile range; TNF-α, tumor necrosis factor-α; PT, prothrombin time; APTT, activated partial thromboplastin time; GFR, glomerular filtration rate; WBC, white blood cell; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ROC, receiver operating characteristics; AUC, area under the curve; OR, odds ratio; 95% CI, 95% confidence interval; PPV, positive predicted value; NPV, negative predicted value; G-CSF, granulocyte-colony stimulating factor; IP-10, interferon gamma-induced protein 10; MCP-1, monocyte chemotactic protein-1; SARS, systemic inflammatory response syndrome.
RESULTS

Patient Characteristics

Electronic medical records of 143 COVID-19 patients older than 60 years old were collected by two physicians from four general isolation wards. After excluding 39 patients who had taken corticosteroids before admission and 10 patients who died within 24 h after admission, 94 participants were enrolled for further analysis (Figure 1).

The median age of the 94 patients was 70 years (IQR 65–76 years), ranging from 60 to 88 years (60–69 years, 47%; 70–79 years, 38%; > 80 years, 15%). There were more males than females in this cohort (56 vs. 44%). Comorbidities were presented in nearly three quarters of these elderly patients, with hypertension being the most common comorbidity, followed by diabetes and coronary heart disease. There were no significant differences in age, sex, and comorbidity between the eosinopenia group (35 patients) and the non-eosinopenia group (59 patients) ($P > 0.05$; Table 1). However, the levels of lymphocyte count, platelet count, aspartate aminotransferase, hypersensitive cardiac troponin I, and serum sodium were significantly different between the two groups ($P < 0.001$; Table 2).

Association Between Eosinopenia and ICU Transfer of Elderly COVID-19 Patients

The median duration from illness onset to hospital admission was 10 days (IQR 7–16 days) for all patients, with 7 days (IQR 5–12 days) for the eosinopenia group and 14 days (IQR 8–19 days) for the non-eosinopenia group, respectively. There was a significantly higher ICU transfer rate in the eosinopenia group than in the non-eosinopenia group (51 vs. 9%, $P < 0.001$; Table 3).

In univariate analysis, a significant inverse association between eosinopenia and ICU transfer of elderly COVID-19 patients was revealed [crude OR 11.44 (95% CI, 3.69–35.43), $P < 0.001$; Table 3]. Furthermore, the inverse association remained significant [adjusted OR 6.12 (95% CI, 1.23–30.33), $P = 0.027$] by multivariate analysis after adjustment for age, lymphocyte count, neutrophil count, CRP, and ferritin levels (Table 4).

Surprisingly, 61% (14 out of 23) of patients transferred to the ICU demonstrated AEC at zero, whereas this phenomenon applied to only 17% (12 out of 71) of patients discharged from the general isolation wards (Table 5).

Association Between Eosinopenia and Traditional Inflammation Indicators

The levels of CRP and ferritin were much higher in the eosinopenia group than in the non-eosinopenia group with significant differences ($P < 0.001$; Figure 2). Additionally, 76 elderly patients in this cohort were tested for serum cytokines. We found that IL-2R, IL-6, IL-8, IL-10, and TNF-α levels were
### TABLE 1 | Basic characteristics of elderly COVID-19 patients on admission (n = 94).

| Characteristics                  | Total   | Eosinopenia | Non-eosinopenia | P      |
|----------------------------------|---------|------------|----------------|--------|
| Patients                         | 94      | 35 (37%)   | 59 (63%)       | –      |
| Age, years                       | 70 (64–78) | 68 (64–78) | 70 (66–75)      | 0.919  |
| 60–69                            | 44 (47%) | 18         | 26             |        |
| 70–79                            | 36 (38%) | 10         | 26             | 0.864  |
| ≥ 80                             | 14 (15%) | 7          | 7              |        |
| Sex                              | –       | –          | –              | 0.752  |
| Male                             | 53 (56%) | 19         | 34             | –      |
| Female                           | 41 (44%) | 16         | 25             | –      |
| Comorbidities                    | 66 (70%) | –          | –              | –      |
| Diabetes                         | 31 (33%) | 11         | 20             | 0.806  |
| Hypertension                     | 43 (46%) | 15         | 28             | 0.665  |
| Coronary heart disease           | 13 (14%) | 5          | 8              | 0.921  |
| Thyroid disease                  | 1 (1%)   | 0          | 1              | –      |
| Parkinson’s disease              | 1 (1%)   | 0          | 1              | –      |
| Systemic lupus erythematosus     | 1 (1%)   | 0          | 1              | –      |

Data are presented as median (interquartile range) or as number (percentage). Student’s t-test or Mann–Whitney U-test was used to compare continuous variables.

### TABLE 2 | Laboratory findings of elderly COVID-19 patients on admission (n = 94).

| Characteristics                  | Total   | Eosinopenia | Non-eosinopenia | P      |
|----------------------------------|---------|------------|----------------|--------|
| WBC, ×10^9/L                     | 5.72 (4.49–7.95) | 5.87 (3.90–8.88) | 5.74 (4.49–7.58) | 0.614  |
| Neutrophils count, ×10^9/L       | 4.08 (2.86–6.18) | 4.88 (2.91–7.68) | 3.53 (2.80–5.82) | 0.063  |
| Lymphocytes count, ×10^9/L       | 1.03 (0.68–1.39) | 0.64 (0.50–0.90) | 1.24 (0.89–1.63) | <0.001 |
| Hemoglobin, g/L                  | 124 (116–136) | 129 (118–142) | 121 (113–129) | 0.012  |
| Platelet count, ×10^9/L          | 222 (154–302) | 155 (137–224) | 249 (186–342) | <0.001 |
| PT, s                            | 14.1 (13.5–14.7) | 14.4 (13.5–15.1) | 14.0 (13.5–14.5) | 0.100  |
| APTT, s                          | 38.1 (35.4–42.1) | 39.7 (36.4–42.3) | 36.7 (35.4–41.1) | 0.238  |
| D-dimer, mg/L                    | 0.93 (0.42–1.89) | 1.16 (0.60–1.90) | 0.69 (0.39–1.65) | 0.043  |
| ALT, U/L                         | 22 (14–32) | 24 (17–38) | 21 (13–28) | 0.095  |
| AST, U/L                         | 25 (19–35) | 34 (25–49) | 22 (19–28) | <0.001 |
| Total bilirubin, mmol/L          | 9.1 (6.5–11.8) | 11.2 (7.9–13.6) | 8.1 (6.3–10.9) | 0.013  |
| Albumin, g/L                     | 34.4 (31.1–38.5) | 33.7 (30.6–38.0) | 35.1 (31.7–39.1) | 0.269  |
| Hs-cTnI, pg/ml                   | 6.7 (3.6–11.4) | 11.9 (7.3–24.4) | 4.9 (2.6–7.2) | <0.001 |
| NT-proBNP, pg/ml                 | 188 (91–374) | 233 (105–885) | 171 (74–269) | 0.013  |
| Potassium, mmol/L                | 4.23 (3.85–4.60) | 4.34 (3.96–4.55) | 4.21 (3.77–4.76) | 0.955  |
| Sodium, mmol/L                   | 140 (137–143) | 138 (135–141) | 141 (139–143) | <0.001 |
| Calcium, mmol/L                  | 2.40 (2.32–2.46) | 2.36 (2.27–2.48) | 2.41 (2.36–2.46) | 0.019  |
| GFR, ml/min                      | 82.3 (71.3–91.3) | 80.3 (61.9–88.0) | 84.2 (75.1–92.8) | 0.060  |
| Creatinine, µmol/L               | 69 (60–87) | 78 (61–93) | 68 (58–82) | 0.054  |
| Blood glucose, mmol/L            | 6.6 (5.7–8.5) | 6.8 (6.0–9.4) | 6.4 (5.3–8.1) | 0.022  |

Data are presented as median (interquartile range). P < 0.05 was considered significant.

PT, prothrombin time; APTT, activated partial thromboplastin time; GFR, glomerular filtration rate; WBC, white blood cell; ALT, alanine aminotransferase; AST, aspartateaminotransferase; Hs-cTnI, hypersensitive cardiac troponin I; NT-proBNP, NT-pro-B-type natriuretic peptide.
TABLE 3 | Characteristics of elderly COVID-19 patients after illness onset (n = 94).

| Characteristics                          | Total | Eosinopenia | Non-eosinopenia | P     |
|------------------------------------------|-------|------------|----------------|-------|
| Number of patients                       | 94    | 35         | 59             | –     |
| From onset to admission (days)           | 10 (7–16) | 7 (5–12)  | 14 (8–19)     | <0.001|
| From general isolation wards to the ICU (number of patients) | 23 (24%) | 18 (51%)  | 5 (9%)        | <0.001|
| From general isolation wards to the ICU (days) | 3 (2–10) | 5 (2–9)    | 3 (2–13)      | 0.927 |

Data are presented as median (interquartile range) or as number (percentage). P < 0.05 was considered as statistically significant.

ICU, intensive care unit.

TABLE 4 | Association between eosinopenia and ICU transfer.

|                      | Eosinopenia and ICU transfer | P     |
|----------------------|-----------------------------|-------|
| Crude OR (95% CI)    | 11.44 (43.69–35.43)         | <0.001|
| Adjusted OR (95% CI) | 6.12 (1.23–30.33)           | 0.027 |

Multiple logistic regression analysis was adjusted for the following variables: age, lymphocyte count, neutrophil count, CRP, and ferritin. P < 0.05 was considered as statistically significant.

OR, odds ratio; CI, confidence interval; CRP, C-reactive protein.

TABLE 5 | Number of patients with AEC of zero and non-zero.

|                                | AEC of zero (number of patients) | AEC of non-zero (number of patients) |
|--------------------------------|----------------------------------|--------------------------------------|
| Number of patients transferred to the ICU | 14                               | 9                                    |
| Number of patients discharged from the general isolation wards | 12                               | 59                                   |

AEC, absolute eosinophil count; ICU, intensive care unit.

significantly higher in the eosinopenia group than in the non-eosinopenia group (P < 0.05; Table 6).

AEC in Predicting ICU Transfer Among Elderly COVID-19 Patients

The AUC of AEC on admission in predicting ICU transfer among elderly COVID-19 patients was 0.828 (95% CI, 0.732–0.923), whereas the AUCs of CRP and ferritin were 0.867 (95% CI, 0.784–0.951) and 0.838 (95% CI, 0.730–0.947), respectively, with no significant difference in the pairwise comparison of ROC curves (P > 0.05; Figure 3 and Table 7). The best cut-off value of AEC was 25 cells/µl, yielding a sensitivity of 91%, a specificity of 71%, a positive predicted value of 51%, and a negative predicted value of 98%, respectively.

DISCUSSION

We conducted the present study to evaluate the association between eosinopenia and ICU transfer prediction of elderly COVID-19 patients from general isolation wards. Our results showed that the eosinopenia group had a significantly higher ICU transfer rate in the eosinopenia group than in the non-eosinopenia group (51 vs. 9%, P < 0.001). In univariate analysis and multivariate analysis, the strong inverse association between eosinopenia and ICU transfer of elderly COVID-19 patients remained significant. Moreover, the AUC of AEC in predicting ICU transfer for elderly COVID-19 patients was equivalent to that of CRP and ferritin. Collectively, AEC could be a valid predictive marker of ICU transfer for elderly COVID-19 patients from general isolation wards.

The mechanism of eosinopenia has not been completely understood in COVID-19. Eosinophils were observed in the infiltrating immune cells of the lungs as revealed by minimal autopsy of dead COVID-19 patients (16). It is assumed that eosinopenia is the redistribution result of circulating eosinophils to the infection locus due to the chemotactic effects of increased cytokines (17). Cytokine storm was observed in severe COVID-19 patients with high levels of various serum cytokines, such as IL-2, IL-7, IL-10, TNF-α, granulocyte-colony stimulating factor (G-CSF), interferon gamma-induced protein 10 (IP-10; CXCL10), and monocyte chemotactic protein-1 (MCP-1) (18–21). We demonstrated that concentrations of classic inflammation indicators, including CRP, ferritin, and several serum cytokines (IL-2R, IL-6, IL-8, IL-10, and TNF-α), were significantly higher in the eosinopenia group than in the non-eosinopenia group. Surprisingly, AEC was zero in more than half (61%) of the patients who eventually transferred to the ICU in this study. This phenomenon described by Shaaban et al. (9) was called “the almost zero eosinophil effect,” probably because of the overwhelming effects of cytokine storm caused by severe infection. The above evidences suggest that eosinopenia in COVID-19 patients may be due to cytokine storm.

The association between AEC and COVID-19 has been explored by limited studies. Eosinopenia was observed in COVID-19 patients with a high percentage up to 47–66% (22, 23). Moreover, compared with mild COVID-19 patients, severe patients had much lower AEC (24–26). Similarly, eosinopenia was detected in 37% of our COVID-19 patients, which was highly correlated with ICU transfer as revealed by multivariate analysis. Therefore, it is suggested that AEC could be a valid predictive marker for severe elderly COVID-19 patients.

Additionally, our results showed that the AUC of AEC on admission for predicting ICU transfer among elderly COVID-19
Huang et al. Eosinophil Predicts Prognosis of COVID-19

**FIGURE 2** | CRP and ferritin levels of elderly COVID-19 patients on admission (n = 94).

**TABLE 6** | Serum cytokine levels of patients (n = 76).

| Characteristics | Total        | Eosinopenia | Non-eosinopenia | P    |
|-----------------|--------------|-------------|-----------------|------|
| IL-2R, U/ml     | 674 (418–918) | 840 (615–1,106) | 596.5 (385–835) | 0.02 |
| IL-6, pg/L      | 11.41 (3.96–39.18) | 40.23 (14.82–80.33) | 7.17 (2.87–14.33) | <0.001 |
| IL-8, pg/L      | 11.9 (7.1–24.7) | 13.9 (8.9–29.0) | 10.3 (5.7–18.8) | 0.045 |
| IL-10, pg/L*    | 5.0 (5.0–7.7) | 8.7 (5.8–13.9) | 5.0 (5.0–5.0) | <0.001 |
| TNF-α, pg/L*    | 8.3 (6.0–10.4) | 9.8 (8.0–12.9) | 7.1 (5.0–9.2) | 0.01 |

*The concentrations of TNF-α and IL-10 were unable to be detected below 5 pg/L. The values below 5 pg/L were replaced by 5 pg/L in statistical analysis.

Data are presented as median (interquartile range). P < 0.05 was considered as statistically significant.

IL-2R, interleukin-2 receptor; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; TNF-α, tumor necrosis factor-α.

**FIGURE 3** | ROC of variables in predicting ICU transfer among elderly COVID-19 patients on admission.

**TABLE 7** | The AUC of variables in predicting ICU transfer among elderly COVID-19 patients on admission.

| Variables | AUC | SE  | 95% CI      |
|-----------|-----|-----|-------------|
| AEC       | 0.828 | 0.0488 | 0.732–0.923 |
| CRP       | 0.867 | 0.0425 | 0.784–0.951 |
| Ferritin  | 0.838 | 0.0554 | 0.730–0.947 |

AUC, area under the curve; ICU, intensive care unit; COVID-19, coronavirus disease 2019; SE, standard error; CI, confidence interval; CRP, C-reactive protein.

Our study has some limitations. Firstly, it is a retrospective study that would provide limited evidence. Secondly, it is a single-center study including only those patients older than 60 years old, but not patients of all ages. Thirdly, the evaluation of AEC is in a single time point on admission without subsequent dynamic changes due to systemic corticosteroids treatment. Hence, a
multicenter study with a larger cohort is required for further validation of our conclusion.

CONCLUSIONS

We demonstrated that AEC on general admission is a valid predictive marker for ICU transfer among elderly COVID-19 patients from general isolation wards and, therefore, can help case triage and optimize ICU utilization. Additionally, AEC is cost-effective, convenient, and fast compared with the expensive and time-consuming CRP and ferritin, making it an appropriate alternative for health care facilities with limited ICU capacity.

DATA AVAILABILITY STATEMENT

The original contributions generated in the study are included in the article/supplementary materials, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. The patients/participants provided their written informed consent to participate in this study.

REFERENCES

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5
2. World Health Organization. Coronavirus Disease (COVID-19). Situation report—133. WHO. Available online at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200601-covid-19-sitrep-133.pdf?sfvrsn=9a56f2ac_4 (accessed June 1, 2020).
3. Bonanad C, García-Blas S, Tarazona-Santanahina FJ, Diez-Villanueva P, Ayesta A, Sanchis Forés J, et al. Coronavirus: the geriatric emergency of 2020. Joint document of the section on geriatric cardiology of the Spanish Society of Cardiology and the Spanish Society of Geriatrics and Gerontology. Revista española de cardiology (English ed). (2020) 73:569–76. doi: 10.1016/j.rec.2020.05.001
4. Li L, Geng S, Yan J. Covid-19 in China: ten critical issues for intensive care medicine. Crit Care. (2020) 24:124. doi: 10.1186/s13054-020-02848-z
5. Vergano M, Bertolini G, Giannini A, Gristina GR, Livigni S, Mistrasletti G, et al. Clinical ethics recommendations for the allocation of intensive care treatments in exceptional, resource-limited circumstances: the Italian perspective during the COVID-19 epidemic. Crit Care. (2020) 24:165. doi: 10.1186/s13054-020-02891-w
6. Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virol. (2020) 92:856–62. doi: 10.1002/jmv.25871
7. Henry BM, de Oliveira MHS, Benoît S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. (2020) 58:1021–8. doi: 10.1515/cclm-2020-0369
8. Hou H, Zhang B, Huang H, Luo Y, Wu S, Tang G, et al. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19. Clin Exp Immunol. (2020) 201:76–84. doi: 10.1111/cei.13450
9. Shaaban H, Daniel S, Sisson R, Slim J, Perez G. Eosinopenia: is it a good marker of sepsis in comparison to procalcitonin and C-reactive protein levels for patients admitted to a critical care unit in an urban hospital? J Crit Care. (2010) 25:570–3. doi: 10.1016/j.jcrc.2010.03.002
21. Chen H, Xuan B, Yan Y, Zhu X, Shen C, Zhao G, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). *Cell Mol Immunol.* (2020) 17:541–3. doi: 10.1038/s41423-020-0401-3

22. Zhang J, Dong X, Cao YY, Yuan YD, Yang YR, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy.* (2020) 75:1730–41. doi: 10.1111/all.14238

23. Yun H, Sun Z, Wu J, Tang A, Hu M, Xiang Z. Laboratory data analysis of novel coronavirus (COVID-19) screening in 2510 patients. *Clin Chim Acta.* (2020) 507:94–7. doi: 10.1016/j.cca.2020.04.018

24. Sun Y, Dong Y, Wang L, Xie H, Li B, Chang C, et al. Characteristics and prognostic factors of disease severity in patients with COVID-19: the Beijing experience. *J Autoimmun.* (2020) 112:102473. doi: 10.1016/j.jaut.2020.102473

25. Sun S, Cai X, Wang H, He G, Lin Y, Lu B, et al. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. *Clin Chim Acta.* (2020) 507:174–80. doi: 10.1016/j.cca.2020.04.024

26. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. *Am J Respir Crit Care Med.* (2020) 201:1372–9. doi: 10.1164/rccm.202003-0543OC

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Huang, Zhang, Liu, Gong, Chen, Ai, Zhu, Zhang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.